Accès ouvert
2026
article
OpenAlex
Joel S. Lwande, Alex Porter, Maeve McQuaid, Eric Waidely et autres
Traditional antimicrobial susceptibility testing (AST) is time-consuming and limited by the need to isolate bacteria. The Bio-Labeling Antibiotic Susceptibility Test (blAST) is a population-level direct-sample ∼6-h phenotypic AST that measures protein synthesis through incorporation of non-canonical amino acids and click chemistry detection. …
us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Marisa Winkler, Paul R. Rhomberg, Kelley A. Fedler, Samuel Edeker et autres
BACKGROUND: Invasive fungal infections (IFIs) are a rising problem among pediatric patients. Antifungal agents have data supporting treatment in pediatric patients of varying ages and infection types but in vitro susceptibility data for large collections of pediatric isolates are lacking, which limits …
us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Marisa Winkler, Samuel Edeker, Abby L Klauer, Paul R. Rhomberg et autres
Abstract Background Manogepix (MGX) targets the fungal Gwt1 enzyme. Fosmanogepix, the prodrug of MGX is undergoing phase 3 clinical trials for treating invasive candidiasis and mould infections. Here, we assessed the in vitro activity of MGX against yeast isolates collected from patients …
us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Marisa Winkler, Samuel Edeker, Abby L Klauer, Paul R. Rhomberg et autres
Abstract Background Manogepix (MGX) is a novel agent targeting the fungal Gwt1 enzyme. This agent is undergoing phase 3 clinical trials for invasive candidiasis and mould infections. Here, we assessed the in vitro activity of MGX against US mould isolates from invasive …
us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Marisa Winkler, Samuel Edeker, Abby L Klauer, Paul R. Rhomberg et autres
Abstract Background Isavuconazole (ISA) is the only US FDA-approved antifungal agent with labeling for the treatment of invasive mucormycosis (IM). The prevalence of IM has risen due to the increased use of immunosuppressive agents and conditions which increase the risk of IM. …
us
(code pays fourni par la source)
Accès ouvert
2026
conference-abstract
OpenAlex
S J Ryan Arends, Paul R. Rhomberg, Mariana Castanheira
Abstract Background EL219 is a novel polyene antifungal drug (formerly known as SF001) currently in preparation for Phase 2 clinical trials (Elion Therapeutics). Through synthetic modifications to amphotericin B, EL219 was designed to improve antifungal activity while reducing the potential for toxicity. …
us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Michael D. Huband, Paul R. Rhomberg, Allison Fuhrmeister, Christopher G Blankers et autres
Abstract Background The VITEK 2 with Advanced Expert System (AES) performs fast identifications and susceptibility testing. AES is based on an extensive, evolving database of MIC distributions/phenotypes, designed to analyze VITEK 2 results for biological validity, infer resistance mechanisms, and provide comments/corrections …
us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Marisa Winkler, John H. Kimbrough, Kelley A. Fedler, Samuel Edeker et autres
Abstract Background Candida auris (CARS) is an emerging infectious threat due to rising infection rates, eradication difficulty, and multidrug resistance. The US Centers for Disease Control (CDC) has tentative resistant (R)-only breakpoints (BP) against CARS for fluconazole (FLC), amphotericin B (AmB), anidulafungin …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Michael D. Huband, Paul R. Rhomberg, Kelley A. Fedler, Christopher G Blankers et autres
• Omadacycline was active against ≥90.0% of Staphylococcus aureus (including MRSA), Staphylococcus lugdunensis, Enterococcus faecalis ( including vancomycin-resistant), Streptococcus anginosus, Streptococcus pneumoniae , and Streptococcus pyogenes isolates from patients with bone/joint infections when acute bacterial skin and skin structure (ABSSSI) breakpoints were …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Joshua M. Maher, Michael D. Huband, Jill M. Lindley, Paul R. Rhomberg et autres
ABSTRACT Sulopenem is an oral and intravenous penem antibiotic in clinical development for treatment of urinary tract and intra-abdominal infections caused by multidrug-resistant pathogens. This study evaluated in vitro antimicrobial activity of sulopenem by post-antibiotic effect (PAE), sub-inhibitory minimal inhibitory concentration PAE …
us
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Marisa Winkler, Paul R. Rhomberg, Abigail Klauer, Samuel Edeker et autres
Abstract Background Ibrexafungerp (IBX) is a novel triterpenoid antifungal agent that was approved by the U.S. FDA for the treatment of vulvovaginal candidiasis (VVC) in 2021. Further studies are ongoing to assess the efficacy of IBX for the treatment of invasive candidiasis …
us
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Marisa Winkler, Paul R. Rhomberg, Abigail Klauer, Mariana Castanheira
Abstract Background Rezafungin (RZF) is a long-acting echinocandin recently approved by the FDA to treat invasive candidiasis (IC) and candidemia. RZF CLSI breakpoints are available for Candida albicans, C. auris (CARS), C. dubliniensis (CDUB), C. glabrata, C. krusei, C. parapsilosis (CPRP), and …
us
(code pays fourni par la source)